EHEdmund Huang

Edmund Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edmund Huang has a total of 293 co-authors. Here are the top co-authors by number of shared publications:

  • Stanley C. Jordan

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA

    12 shared publications
  • Alice Peng

    Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA

    7 shared publications
  • Reiad Najjar

    Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA

    7 shared publications
  • Stanley C. Jordan

    Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA

    7 shared publications
  • Supreet Sethi

    Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA

    7 shared publications
  • Ashley A. Vo

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA

    6 shared publications

Latest Publications

  • Open Access

    Anti-Nephrin Antibodies in Focal Segmental Glomerulosclerosis Recurrence After Transplantation: A Multicenter Study from the TANGO Consortium

    by Marie-Camille Lafargue, Frank Hullekes, Juliette Leon, Rucháma Verhoeff, Rodrigo Gassen, Suvra Mitra, Antonio M. Fontanella, Adela D. Mattiazzi, George W. Burke, Alessia Fornoni, et al.

  • Performance of the Integrative Box (iBox) Prognostication System in African American Kidney Transplant Recipients

    by Agathe Truchot, Yannis Lombardi, Marc Raynaud, Olivier Aubert, Gillian Divard, Thibaut Thalamas, Brad Astor, Didier Mandelbrot, Sandesh Parajuli, Kenneth A. Newell, et al.

    Key Points: The integrative box showed accurate discrimination, overall fit, and clinical utility in 3866 kidney transplant recipients from North America. Predictive performance was maintained in African American and non-African American kidney transplant recipients. These results support the robustness of the integrative box as a risk prediction tool. Background: The integrative box (iBox) is a validated prognostication system that predicts long-term death-censored graft loss in kidney transplant recipients, but its performance in the specific population of African American recipients has not been fully studied. Methods: We conducted a multicenter study including 3866 kidney transplant recipients from North America, of whom 1040 (27%) were African American, to assess the impact of race on the iBox's performance in predicting graft loss. Discrimination, calibration, overall fit, and clinical utility were evaluated in the whole cohort and in African American and non-African American recipients. Results: Performance metrics for the prediction of graft loss were similar in both subgroups in discrimination (C-index 0.80 [95% confidence interval (CI), 0.77 to 0.83] in African American recipients and 0.83 [95% CI, 0.81 to 0.85] in non-African American recipients, P = 0.07) and observed/expected ratios (1.08 [95% CI, 0.95 to 1.23] and 0.99 [95% CI, 0.88 to 1.10], respectively, P = 0.28). No significant interaction between iBox score values and race was found in multivariable analysis stratified by transplant center ( P = 0.24 for the interaction term). The results were consistent between the subgroups regardless of the equation used to estimate eGFR (Kidney Recipient Specific, CKD-Epidemiology Collaboration, or Modification of Diet in Renal Disease), but with variations in calibration across equations. Conclusions: The iBox prognostication system showed accurate discrimination, overall fit, and clinical utility up to 7 years after risk evaluation in African American and non-African American kidney transplant recipients, supporting its robustness in this population. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT03474003.

  • Open Access

    CTLA4-Ig + Anti-IL-6/IL-6R Treatment Results in Long-term Allograft Survival and Function in Highly HLA-sensitized Patients

    by Stanley C. Jordan, Sindhu Chandran, Noriko Ammerman, Edmund Huang, Jun Shoji, Xiaohai Zhang, Alice Peng, Bongha Shin, David Thomas, Reiad Najjar, et al.

    Background.: Highly HLA-sensitized (HS) patients are at increased risk for cell-mediated rejection (CMR)/antibody-mediated rejection (AMR) posttransplant and require intense immunosuppression to prevent these events. HS patients who experience calcineurin inhibitor (CNI) neuro/nephrotoxicity have few options as conversion to CNI-free regimens with cytotoxic T-lymphocyte-associated antigen (CTLA4)-Ig may risk donor specific antibody (DSA) rebound, CMR, and AMR. This remains an unmet medical need. Anti-interleukin (IL)-6/IL-6R treatment is useful in treating AMR and CMR and preventing rejection in HS patients after transplantation (tx). Here, we examined the utility of combining CTLA4-Ig with anti-IL-6/IL-6R treatment in 4 HS patients with CNI toxicity. Methods.: Four HS patients (3 with calculated panel reactive antibodies >97% at tx and 1 who developed chronic-active AMR (c-aAMR) 14 y post-tx were evaluated. Two patients, 100% calculated panel reactive antibody and +flow crossmatch at transplantation, were desensitized with plasma exchange + clazakizumab (anti-IL-6) and maintained on clazakizumab post-tx and transitioned from CNI to CTLA4-Ig. Two patients treated with anti-IL-6R (tocilizumab) were transitioned to CTLA4-Ig at 2 and 11 y post-tx. Patients were monitored for renal function (RF), DSA, de novo DSA (dn-DSA), immune cell subsets, and patient and graft survival. Results.: Clazakizumab and tocilizumab treated patients showed improvements in RF, with elimination of existing DSAs, except for 1 patient and no dn-DSAs (>6 y). We also saw reductions in CD8 + T EFF/MEM , T FH , B MEM , and NK cells post-CTLA4-Ig + Anti-IL-6/IL-6R treatment. T REG and B REG cell populations also increased, suggesting, but not confirming, possible immune modulation. Conclusions.: Combining CTLA4-Ig + anti-IL-6/IL-6R appears to offer benefits in sustaining RF, DSA reduction, possibly immune cell modulation, and prevention of dn-DSA. Importantly, CNI toxicity abated in all patients.

  • Normalization of nCounter Gene Expression Data Alters Molecular Diagnostics in Kidney Transplantation

    by Alexis Piedrafita, Marta Sablik, Evgenia Preka, Valentin Goutaudier, Zeynep Demir, Fariza Mezine, Gillian Divard, Jessy Dagobert, Blaise Robin, Agathe Truchot, et al.

    Key Points: Normalization methods affected the performance of gene-based diagnostic classifiers for kidney transplant rejection across a large multicenter cohort. Complex normalization reduced classifier performance by overcorrecting signal, while simpler methods preserved rejection signature and key robustness. By identifying optimal normalization methods, this work advances a standardized preprocessing framework for molecular diagnostics in transplantation. Background: The Banff 2022 classification endorses intragraft gene expression profiling using the Banff Human Organ Transplant (B-HOT) consensus gene panel for rejection diagnosis. However, lack of standardized analytical pipelines, including data normalization, limits clinical implementation, with its effect on diagnostic performance yet to be determined. Methods: We evaluated ten normalization methods in 868 kidney allograft biopsies from nine European and North American centers, all Banff-graded and B-HOT–profiled on nCounter, comprising derivation ( n =441), internal ( n =186), and external ( n =241) validation cohorts. Each method was assessed through its downstream impact on ( 1 ) gene count stability, ( 2 ) differential expression and cross-platform concordance with RNA sequencing (RNA-seq) data, and ( 3 ) discrimination and calibration of predictive models for antibody-mediated rejection (AMR) and T -cell–mediated rejection (TCMR). Results: Most methods improved count stability and showed high concordance with RNA-seq for overall gene expression. They also produced robust differential expression signatures consistent with those detected by RNA-seq, except for RUVSeq and RCRNorm , which identified fewer differentially expressed genes and showed lower concordance. In the overall validation cohort ( n =427), diagnostic performance was consistently high across nSolver -based approaches, nanostringr , NanoStringDiff , MetaNorm , and RCRNormFast (AMR, area under the ROC curve [AUROC], 0.88–0.91; area under precision-recall curves [AUPRC], 0.86–0.89; TCMR AUROC, 0.90–0.92; AUPRC, 0.78–0.83). Performance declined with RCRNorm (AMR AUROC/AUPRC, 0.55/0.41; TCMR, 0.53/0.18) and, for TCMR, with RUVSeq (AUROC, 0.84–0.85; AUPRC, 0.64–0.65). Calibration was satisfactory for most methods, except for RCRNorm and for TCMR models after RUVSeq . Conclusions: Normalization choice significantly impacted gene expression profiles and diagnostic classifier performance. Most methods, including nSolver-based pipelines, achieved robust discrimination for both AMR and TCMR. Complex methods, including RCRNorm, and RUVSeq for TCMR, reduced performance, with simpler approaches consistently outperforming them for B-HOT–based molecular diagnostics.


  • Top Cited Papers
    Open Access

    The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning

    by Maarten Naesens, Candice Roufosse, Lynn D. Cornell, Mark Haas, Roslyn B. Mannon, Marjan Afrouzian, Enver Akalin, Nada Alachkar, Mariam P. Alexander, Serena M. Bagnasco, et al.


  • Open Access

    Tocilizumab Treatment for Microvascular Inflammation and Chronic Active Antibody-mediated Rejection in Kidney Transplantation

    by Edmund Huang, Michie Adjei, Alice Peng, Reiad Najjar, Jun Shoji, Sindhu Chandran, Ashley Vo, Stanley C. Jordan

    Background.: Interleukin-6 (IL-6) is an important driver of humoral immunity and a target for treatment of antibody-mediated rejection (AMR) in kidney transplantation. Data on IL-6 inhibition for treatment of AMR are mixed and their efficacy remains inconclusive. In this retrospective observational study, we investigated the association of monthly tocilizumab infusions with the trajectory of estimated glomerular filtration rate (eGFR) among kidney transplant patients with histologic features of chronic active AMR. Methods.: Through institutional database review, 85 adult kidney transplant patients with histologic features of chronic active AMR treated with monthly tocilizumab 8 mg/kg intravenous infusions were identified. Piecewise linear mixed effects models were fitted to compare eGFR trajectories 12 mo before and after tocilizumab initiation. Results.: The eGFR declined at a rate of –0.70 mL/min/1.73 m2/mo (95% confidence interval, –1.03 to –0.36) preceding tocilizumab initiation and stabilized after treatment onset to a slope of –0.07 (–0.35 to 0.21) mL/min/1.73 m2/mo (slope difference: 0.59 [0.22-0.97] mL/min/1.73 m2/mo, P = 0.002).The distribution of the sum mean fluorescence intensity of donor specific antibodies (DSA) among 65 DSA+ patients remained unchanged from baseline to 1 y after treatment; however, 14 of 65 DSA+ patients (22%) no longer had DSA at 1 y. There was 1 graft loss and 2 deaths, both COVID-19-related, by 12 mo after treatment onset. Conclusions.: This study suggests that monthly treatment with the anti-IL-6 receptor monoclonal antibody, tocilizumab, may stabilize allograft function among kidney transplant patients with chronic active AMR and that further studies to confirm its efficacy should be conducted.


  • Exosome-primed T cell immunity is facilitated by complement activation

    by Sara Alibrandi, Angela Clemens, Yansui Li, William J. Shufesky, Ashley Vo, Noriko Ammerman, Edmund Huang, Simon C. Watkins, Peter Heeger, Stanley Jordan, et al.


  • Top Cited Papers
    Open Access

    Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies

    by Jonathan S. Bromberg, Daniel C. Brennan, David J. Taber, Matthew Cooper, Sanjiv Anand, Enver Akalin, Edmund Huang, Jeffrey A. Klein, Renata Glehn-Ponsirenas, Jeffrey Rogers, et al.


  • Open Access

    Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial

    by Edmund Huang, Noriko Ammerman, Ashley Vo, Jean Hou, Sanjeev Kumar, Nicole Badash, Ben Falk, Kathleen Hernando, Matthew Gillespie, Irene K. Kim, et al.


  • Top Cited Papers
    Open Access

    Cell-free DNA for the detection of kidney allograft rejection

    by Olivier Aubert, Cindy Ursule-Dufait, Romain Brousse, Juliette Gueguen, Maud Racapé, Marc Raynaud, Elisabet Van Loon, Angelica Pagliazzi, Edmund Huang, Stanley C. Jordan, et al.

    Donor-derived cell-free DNA (dd-cfDNA) is an emerging noninvasive biomarker that has the potential to detect allograft injury. The capacity of dd-cfDNA to detect kidney allograft rejection and its added clinical value beyond standard of care patient monitoring is unclear. We enrolled 2,882 kidney allograft recipients from 14 transplantation centers in Europe and the United States in an observational population-based study. The primary analysis included 1,134 patients. Donor-derived cell-free DNA levels strongly correlated with allograft rejection, including antibody-mediated rejection (P < 0.0001), T cell-mediated rejection (P < 0.0001) and mixed rejection (P < 0.0001). In multivariable analysis, circulating dd-cfDNA was significantly associated with allograft rejection (odds ratio 2.275; 95% confidence interval (CI) 1.902–2.739; P < 0.0001) independently of standard of care patient monitoring parameters. The inclusion of dd-cfDNA to a standard of care prediction model showed improved discrimination (area under the curve 0.777 (95% CI 0.741–0.811) to 0.821 (95% CI 0.784–0.852); P = 0.0011) and calibration. These results were confirmed in the external validation cohorts (n = 1,748) including a cohort of African American patients (n = 439). Finally, dd-cfDNA showed high predictive value to detect subclinical rejection in stable patients. Our study provides insights on the potential value of assessing dd-cfDNA, in addition to standard of care monitoring, to improve the detection of allograft rejection. ClinicalTrials.gov registration: NCT05995379.